Does TOCILIZUMAB Cause Interstitial lung disease? 1,229 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 1,229 reports of Interstitial lung disease have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 1.3% of all adverse event reports for TOCILIZUMAB.
1,229
Reports of Interstitial lung disease with TOCILIZUMAB
1.3%
of all TOCILIZUMAB reports
154
Deaths
418
Hospitalizations
How Dangerous Is Interstitial lung disease From TOCILIZUMAB?
Of the 1,229 reports, 154 (12.5%) resulted in death, 418 (34.0%) required hospitalization, and 148 (12.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for TOCILIZUMAB.
What Other Side Effects Does TOCILIZUMAB Cause?
Drug ineffective (32,342)
Rheumatoid arthritis (20,652)
Pain (18,384)
Off label use (18,256)
Arthralgia (15,536)
Joint swelling (14,831)
Fatigue (13,802)
Rash (12,327)
Drug intolerance (11,952)
Contraindicated product administered (11,547)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TOCILIZUMAB Alternatives Have Lower Interstitial lung disease Risk?
TOCILIZUMAB vs TOCILIZUMAB-AAZG
TOCILIZUMAB vs TOCOPHEROL
TOCILIZUMAB vs TOFACITINIB
TOCILIZUMAB vs TOFERSEN
TOCILIZUMAB vs TOLNAFTATE